Who is the assignee on this patent?

Protagonist Therapeutics Inc, Protaganist Therapeutics Inc

What technology area does this patent fall under?

Primary CPC classification A61P1/04. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Patent metadata
Field	Value
Publication number	US-10787490-B2
Application number	US-201615745371-A
Country	US
Kind code	B2
Filing date	Jul 15, 2016
Priority date	Jul 15, 2015
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.

First claim

Opening claim text (preview).

What is claimed is: 1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is: (SEQ ID NO: 1115) [Palm]-[isoGlu]-[PEG4]-[Pen]-NTWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1116) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2-Nal]- [Aib]-[Lys(PEG4-isoGlu-Palm)]-NN-NH 2 ; (SEQ ID NO: 1117) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(Ac)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1118) [Octanyl]-[IsoGlu]-[PEG4]-[Pen]-NTWQ-[Pen]-[Phe[4- (2-aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1119) [Octanyl]-[PEG4]-[Pen]-NTWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1120) [Palm]-[PEG4]-[Pen]-NTWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1121) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-(2- Nal]-[Aib]-[Lys(PEG4-Octanyl)]-NN-NH 2 ; (SEQ ID NO: 1122) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-(2- Nal]-[Aib]-[Lys(PEG4-Palm)]-NN-NH 2 ; (SEQ ID NO: 1123) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)-(PEG4-Palm)]-(2-Nal]-[Aib]- [Lys(Ac)]NN-NH 2 ; (SEQ ID NO: 1124) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)-(PEG4- Lauryl)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1125) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(PEG4-Palm)-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1126) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(PEG4-Lauryl)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1127) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)-(PEG4- IsoGlu-Palm)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1128) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)-(PEG4- IsoGLu-Lauryl)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1129) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(PEG4-IsoGlu-Palm)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1130) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-a-Me- K(PEG4-IsoGlu-Lauryl)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1131) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(IVA)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1132) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(Biotin)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1133) Ac-[Pen]-QTWQ-[Pen]-Phe(4-CONH 2 )-[2-Nal]-[a- MeLys(Octanyl)]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1134) Ac-[Pen]-[Lys(IVA)]-TWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1135) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2- Nal]-[Aib]-[Lys(Ac)]-[Lys(IVA)]-N-NH 2 ; (SEQ ID NO: 1136) Ac-[Pen]-[Lys(Biotin)]-TWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1137) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2- Nal]-[Aib]-[Lys(Ac)]-[Lys(Biotin)]-N-NH 2 ; (SEQ ID NO: 1138) Ac-[Pen]-[Lys(Octanyl)]-TWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]-[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1139) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2- Nal]-[Aib]-[Lys(Ac)]-[Lys(octanyl)]-N-NH 2 ; (SEQ ID NO: 1140) Ac-[Pen]-[Lys(Palm)]-TWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]--[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1141) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2- Nal]-[Aib]-[Lys(Ac)]-Lys(Palm)]-N-NH 2 ; (SEQ ID NO: 1142) Ac-[Pen]-[Lys(PEG8)]-TWQ-[Pen]-[Phe[4-(2- aminoethoxy)]-[2-Nal]--[Aib]-[Lys(Ac)]-NN-NH 2 ; (SEQ ID NO: 1143) Ac-[Pen]-NTWQ-[Pen]-[Phe[4-(2-aminoethoxy)]-[2- Nal]-[Aib]-[Lys(Ac)]-[Lys(PEG8)]-N-NH 2 ; (SEQ ID NO: 1144) Ac-[Pen]-K(Peg11-Palm)TWQ-[Pen]-[Phe[4-(2- ami

Assignees

Inventors

Classifications

A61P1/04Primary
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
A61K38/00
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
C07K14/4703Primary
Inhibitors; Suppressors · CPC title

Patent family

Related publications grouped by family.

View patent family 68054785

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10787490B2 cover?: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.
Who is the assignee on this patent?: Protagonist Therapeutics Inc, Protaganist Therapeutics Inc
What technology area does this patent fall under?: Primary CPC classification A61P1/04. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).